|In Silico Approach for Predicting Toxicity of Peptides and Proteins|
S Gupta, P Kapoor, K Chaudhary, A Gautam, R Kumar, ...
PloS one 8 (9), e73957, 2013
|In silico models for designing and discovering novel anticancer peptides|
A Tyagi, P Kapoor, R Kumar, K Chaudhary, A Gautam, GPS Raghava
Scientific reports 3 (1), 1-8, 2013
|In silico approaches for designing highly effective cell penetrating peptides|
A Gautam, K Chaudhary, R Kumar, A Sharma, P Kapoor, A Tyagi, ...
Journal of translational medicine 11 (1), 1-12, 2013
|CPPsite: a curated database of cell penetrating peptides|
A Gautam, H Singh, A Tyagi, K Chaudhary, R Kumar, P Kapoor, ...
Database 2012, 2012
|TumorHoPe: a database of tumor homing peptides|
P Kapoor, H Singh, A Gautam, K Chaudhary, R Kumar, GPS Raghava
PLoS One 7 (4), e35187, 2012
|CancerDR: cancer drug resistance database|
R Kumar, K Chaudhary, S Gupta, H Singh, S Kumar, A Gautam, P Kapoor, ...
Scientific reports 3 (1), 1-6, 2013
|Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas|
FC Geyer, A Li, AD Papanastasiou, A Smith, P Selenica, KA Burke, ...
Nature communications 9 (1), 1-16, 2018
|An in silico platform for predicting, screening and designing of antihypertensive peptides|
R Kumar, K Chaudhary, J Singh Chauhan, G Nagpal, R Kumar, ...
Scientific reports 5 (1), 1-10, 2015
|Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells|
J Nikkilä, R Kumar, J Campbell, I Brandsma, HN Pemberton, F Wallberg, ...
British journal of cancer 117 (1), 113-123, 2017
|Peptide toxicity prediction|
S Gupta, P Kapoor, K Chaudhary, A Gautam, R Kumar, GPS Raghava
Computational Peptidology, 143-157, 2015
|Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome|
AB Holmes, C Corinaldesi, Q Shen, R Kumar, N Compagno, Z Wang, ...
Journal of Experimental Medicine 217 (10), 2020
|The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers|
B Weigelt*, R Bi*, R Kumar*, P Blecua, DL Mandelker, FC Geyer, F Pareja, ...
JNCI: Journal of the National Cancer Institute 110 (9), 1030-1034, 2018
|E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer|
I Bajrami, R Marlow, M van de Ven, R Brough, HN Pemberton, J Frankum, ...
Cancer Discovery 8 (4), 498-515, 2018
|Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors|
F Pareja, AH Brandes, T Basili, P Selenica, FC Geyer, D Fan, ...
Nature communications 9 (1), 1-13, 2018
|Tumor homing peptides as molecular probes for cancer therapeutics, diagnostics and theranostics|
A Gautam, P Kapoor, K Chaudhary, R Kumar, GPS Raghava, ...
Current medicinal chemistry 21 (21), 2367-2391, 2014
|Computational approach for designing tumor homing peptides|
A Sharma, P Kapoor, A Gautam, K Chaudhary, R Kumar, JS Chauhan, ...
Scientific reports 3 (1), 1-7, 2013
|Precision radiotherapy: reduction in radiation for oropharyngeal cancer in the 30 ROC trial|
N Riaz, E Sherman, X Pei, H Schöder, M Grkovski, R Paudyal, N Katabi, ...
JNCI: Journal of the National Cancer Institute 113 (6), 742-751, 2021
|Prioritization of anticancer drugs against a cancer using genomic features of cancer cells: A step towards personalized medicine|
S Gupta, K Chaudhary, R Kumar, A Gautam, JS Nanda, SK Dhanda, ...
Scientific reports 6 (1), 1-11, 2016
|Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression|
CW Ashley, ADC Paula, R Kumar, D Mandelker, X Pei, N Riaz, ...
Gynecologic oncology 152 (1), 11-19, 2019
|MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB‐NFIB fusion gene|
J Kim, FC Geyer, LG Martelotto, CKY Ng, RS Lim, P Selenica, A Li, ...
The Journal of pathology, 2017